Sodium zirconium cyclosilicate 10g oral powder sachets

Background: Hyperkalemia is a common and potentially life-threatening complication in patients with chronic kidney disease (CKD). Methods: This systematic review followed the PRISMA 2020 guidelines. A comprehensive literature search was conducted using PubMed, ScienceDirect, and the Cochrane Library to identify randomized controlled trials and comparative observational studies involving adult patients with CKD and hyperkalemia. Studies comparing sodium zirconium cyclosilicate (SZC) with polystyrene sulfonate–based binders and reporting efficacy or safety outcomes were included. Data extraction and risk of bias assessment were performed, and a qualitative synthesis of results was conducted due to study heterogeneity. Results: Eight studies were included in the qualitative analysis, comprising seven interventional and hospital-based observational studies involving 690 patients and one large nationwide cohort including more than 70,000 patients. In acute settings, SZC achieved rapid reductions in serum potassium, with greater or comparable efficacy to polystyrene sulfonate–based binders. In chronic management, SZC was associated with earlier normalization and more sustained potassium control. Safety outcomes were generally comparable, with favorable tolerability and patient preference observed for SZC. Discussion: The included studies consistently demonstrated effective potassium lowering with SZC across acute and chronic settings. While heterogeneity and the predominance of observational data limit causal inference, the overall findings support the clinical utility of SZC, particularly in facilitating long-term potassium control and treatment adherence. Conclusion: SZC represents an effective and well-tolerated alternative to polystyrene sulfonate–based binders for the management of hyperkalemia in patients with CKD. Further well-designed randomized studies are warranted to confirm long-term clinical benefits.

Abstract licence: CC BY-SA 4.0

Hyperkalemia, characterized by elevated serum potassium levels, is a common and serious condition in patients with Chronic Kidney Disease (CKD). Sodium zirconium cyclosilicate (SZC) is an oral medication that enhances potassium excretion in the feces by selectively capturing potassium ions in exchange for sodium and hydrogen ions. This meta-analysis aims to evaluate the efficacy of SZC in managing hyperkalemia in CKD patients. A comprehensive literature search was conducted up to December 28, 2024, across databases including PubMed, ScienceDirect, and the Cochrane Library, using specific keywords related to sodium zirconium cyclosilicate and hyperkalemia in CKD. Inclusion criteria focused on studies assessing the effect of SZC on serum potassium levels in CKD patients with hyperkalemia. A total of 4 studies were included for quantitative synthesis, and the risk of bias was assessed using the RoB-2 tool. The meta-analysis revealed a significant mean difference in serum potassium levels between the SZC and placebo groups, with a reduction of -0.53 (95% CI -0.65 to -0.41; p < 0.00001). The analysis indicated moderate heterogeneity (I² = 51%). SZC demonstrated rapid efficacy in lowering serum potassium levels, achieving significant reductions within 48 hours of treatment. Sodium zirconium cyclosilicate is effective in rapidly reducing serum potassium levels in patients with hyperkalemia associated with Chronic Kidney Disease. Its ability to maintain normokalemia for up to four weeks highlights its potential as a preferred treatment option for acute hyperkalemia. Further research with larger sample sizes is warranted to confirm these findings and explore long-term outcomes.

Abstract licence: CC BY 4.0

BackgroundOral sodium zirconium cyclosilicate (SZC) is a novel potassium binder capable of achieving a rapid reduction of serum potassium (sK+) and maintaining a long-term normokalemia. We undertook a meta-analysis to summarize and evaluate the effects surrounding SZC in patients with hyperkalemia.MethodWe searched data sources from MEDLINE (from 1950 to Sep 2020), EMBASE (from 1970 to Sep 2020), and the Cochrane Library database (from 1950 to Sep 2020) for eligible studies. All randomized controlled trials (RCTs) regarding comparison of therapeutic effects of SZC in hyperkalemia participants were included.ResultsSeven studies, including 1697 patients with hyperkalemia, were analyzed. SZC significantly reduced mean sK+ (-0.42 mmol/L; 95% CI: -0.63 to -0.20 mmol/L, p = 0.0001) compared with placebo, with a significantly greater proportion of patients with normokalemia (RR 3.48, 95% CI 1.49 to 8.11, p = 0.004). Subgroup analyses showed that the longer durations of SZC treatment, the greater magnitudes of potassium reduction when compared with those of placebo (p between subgroups = 0.01) at correction phase. Besides, it also demonstrated sK+ tended to decrease more in patients who got longer treatment or larger dosage of SZC at maintenance phase; however, the difference did not reach statistical significance. Additionally, the drug was equally effective in studies with larger than 50% of patients with chronic kidney disease (CKD) or diabetes or patients using renin-angiotensin aldosterone system inhibitor (RAAS) inhibitors (all p ConclusionsSZC effectively decreased the sK+ level in patients with hyperkalemia within 48 h and had benefits in the long-term control of serum potassium in patients who continued to receive SZC with a favorable safety profile from available data.

Abstract licence: CC BY